HCRTR1, HCRTR2: Orexin receptor
Family in Homo sapiens that 5 drugs act on.
- Drugs that act on it: 5
- Approved: 2
- In phases 1 to 3: 3
- Sponsors: 4
Who is on it, and how far along
Every drug ChEMBL records acting on HCRTR1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 4
- Other 1
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- Merck & Co. (MSD)240%
- Idorsia120%
- Midnight Pharma, LLC120%
- Taisho Pharmaceutical Co., Ltd.120%
| Daridorexant | Approved | Idorsia | Small molecule | Antagonist | 16 |
| Suvorexant | Approved | Merck & Co. (MSD) | Small molecule | Antagonist | 13 |
| Almorexant | Phase 3 | Midnight Pharma, LLC | Small molecule | Antagonist | 0 |
| ORN-0829 hydrate | Phase 3 | Taisho Pharmaceutical Co., Ltd. | Other | Antagonist | 0 |
| Filorexant | Phase 2 | Merck & Co. (MSD) | Small molecule | Antagonist | 0 |
| A Multicenter Observational Study of Daridorexant in the Treatment of Insomnia | Daridorexant | — | Not yet recruiting | Shanghai Mental Health Center | Sep 29, 2026 |
| A Trial to See if Daridorexant Can Help Adults and Elderly People With Insomnia Sleep Better During the Night and Function Better During the Day | Daridorexant | Phase 3 | Recruiting | Idorsia Pharmaceuticals Ltd. | Sep 28, 2026 |
| Daridorexant for Sleep Disturbance in Adults With Liver Cirrhosis | Daridorexant | Phase 4 | Not yet recruiting | Wang Fengmei | Sep 21, 2026 |
| Study on the Management of COMISA | Daridorexant | Not applicable | Recruiting | University Hospital, Grenoble | Aug 4, 2026 |
| Evaluating the Efficacy and Safety of Daridorexant Transition From BZRAs in Insomnia Patients(EASY-TIP) | Daridorexant | Phase 4 | Not yet recruiting | Xuanwu Hospital, Beijing | Jul 29, 2026 |
| Daridorexant for People With Insomnia and Alcohol Use Disorder Study | Daridorexant | Phase 2 | Not yet recruiting | Sterling McPherson | Jul 14, 2026 |
| Suvorexant 3 - PE-PC | Suvorexant | Phase 4 | Not yet recruiting | Northern California Institute of Research and Education | Jul 7, 2026 |
| Efficacy and Safety of Daridorexant in Patients With Major Depressive Disorder and Insomnia | Daridorexant | Phase 4 | Not yet recruiting | Institut d'Investigació Biomèdica de Bellvitge | Apr 29, 2026 |
| Daridorexant for Alcohol Use Disorder | Daridorexant | Phase 2 | Not yet recruiting | Johns Hopkins University | Apr 15, 2026 |
| Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking | Suvorexant | Phase 2 | Recruiting | Ohio State University | Oct 9, 2025 |
| Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial | Suvorexant | Phase 2 | Recruiting | Marianne Goodman | Mar 3, 2025 |
| The Effects of Orexin Antagonism on Fear Extinction in PTSD | Suvorexant | Phase 4 | Recruiting | VA Office of Research and Development | Jan 23, 2025 |
| Suvorexant for Treatment of AUD and PTSD | Suvorexant | Phase 2 | Recruiting | Pharmacotherapies for Alcohol and Substance Use Disorders Alliance | Nov 7, 2024 |
| A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098) | Suvorexant | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | Oct 24, 2024 |
| Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms | Suvorexant | Phase 1 / Phase 2 | Recruiting | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Jul 3, 2024 |
| Suvorexant and Alcohol | Suvorexant | Early phase 1 | Recruiting | William Stoops | Mar 22, 2024 |
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3307226, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets